$CLGN

CollPlant Biotechnologies' subsidiary LightSolver filed a provisional patent for its laser-based computing platform, focusing on solving physical and engineering problems. The tech addresses complex equations in heat transfer, diffusion, and fluid-flow. CEO Dr. Ruti Ben-Shlomi highlighted the filing as a key milestone in securing core innovations. CollPlant operates in computing and biotech sectors, including 3D bioprinting and medical aesthetics.

CollPlant's subsidiary, LightSolver, filed a U.S. provisional patent for expanding its photonic computing platform to solve complex scientific and engineering simulations. The invention enables the platform to address partial differential equations, broadening its applications. According to the company, this filing strengthens LightSolver's IP portfolio and supports its strategy for high-performance computing. CollPlant (Nasdaq: CLGN) operates in deep-tech computing and biotechnology.

CollPlant Biotechnologies reported a GAAP EPS of -$0.87 and revenue of $11.43M, up 116.1% year-over-year. The company reaffirmed its FY 2026 revenue growth guidance of 50% to 100% compared to FY 2025, according to a press release.

Collplant ADR (CLGN) reported Q3 EPS of -$1.89, beating estimates by $0.56, but revenue of $108K missed expectations of $480K. The stock is up 11.11% in 3 months but down 84.63% in 12 months. InvestingPro rates its financial health as 'weak performance'.

CollPlant reported H1 2026 revenue of $181,000, down from $2.234M in 2025, with a net loss of $5.823M, wider than the $4.799M loss in 2025. The company warned about liquidity concerns, stating it lacks sufficient funds to operate for 12 months. Post-quarter, CollPlant raised $7.14M from a June offering and warrant exercises.

CollPlant Biotechnologies Ltd (CLGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Se

CollPlant (CLGN) reported Q2 2026 financial results, with revenues of $108,000, down from $179,000 in Q2 2025. The company acquired LightSolver, entering the high-performance computing market, and appointed Dr. Ruti Ben Shlomi to its board. CollPlant also continues to focus on regenerative medicine. GAAP net loss for Q2 2026 was $2.7 million, or $1.89 per share.

CollPlant (CLGN) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing a prior deficiency matter. The company's shares met the criteria for ten consecutive days. CEO Yehiel Tal expressed commitment to advancing the company's technological and commercial roadmap, including developments in photonic computing and biotechnology.

CollPlant (CLGN) will host an investor webinar on September 17, 2026, to introduce its newly acquired subsidiary LightSolver, which focuses on photonic computing. The event will discuss LightSolver's technology, roadmap, and commercialization plans, marking CollPlant's diversification into advanced computing alongside its existing regenerative medicine and 3D bioprinting businesses.

CollPlant (CLGN) granted its Deputy CEO and CFO, Rotem Eran, 510,372 restricted share units (RSUs) on September 3, 2026. The RSUs vest over five years, with 30% vesting in 2027 and the remainder in equal installments. After a 1-for-10 reverse stock split, Eran's total holdings amount to 516,372 ordinary-share equivalents.